BioStem Technologies, Inc. Takes Major Steps Towards Nasdaq Listing
BioStem Technologies, Inc. (OTC: BSEM) is making significant strides in its journey to uplist on the Nasdaq Stock Market. The company, known for its innovative development, manufacturing, and commercialization of biologics derived from placental tissues, recently filed a Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). This registration, submitted on September 27, 2024, showcases BioStem's commitment to increased transparency and adherence to stringent corporate governance standards.
Importance of the Form 10 Registration
The filing of the Form 10 is a crucial step in BioStem's plan to transition onto Nasdaq. By becoming a fully reporting entity with the SEC, the company aims to enhance investor confidence by providing comprehensive insights into its operations and financial health. BioStem anticipates that achieving this reporting status will not only elevate its market credibility but also open doors to greater visibility and access to capital. Such access is vital for supporting BioStem’s growth objectives and maximizing shareholder value over time.
Commitment to Corporate Governance
With the filing of the Form 10, BioStem reinforces its dedication to robust corporate governance practices. This initiative indicates that the company is committed to maintaining high standards of accountability and transparency. Once the registration statement takes effect, which is expected to occur 60 days post-filing, BioStem's operations will adhere to standard reporting obligations, including quarterly and annual financial reports.
Meeting Nasdaq’s Listing Requirements
BioStem’s pursuit of a listing on Nasdaq hinges on fulfilling the necessary regulatory criteria essential for approval. Until the uplisting is accomplished, the company's stock will remain traded on the OTC market under the ticker symbol “BSEM.” The management team is fully focused on enhancing shareholder value through this uplisting, as the Nasdaq platform provides enhanced visibility, liquidity, and trading efficiencies for both institutional and retail investors.
Enhancing Financial Reporting Structures
In preparation for this pivotal shift, BioStem has made significant investments to strengthen its compliance framework. This includes the completion of two years' worth of audited financial statements. Such measures ensure that BioStem is well-positioned to meet the rigorous standards of a major exchange.
CEO's Vision on Uplisting
Jason Matuszewski, CEO of BioStem Technologies, expressed that pursuing a major exchange listing is a landmark decision, especially during a time of impressive revenue growth. He emphasized that uplisting to Nasdaq aligns with the company’s strategic objectives to enhance market presence and accessibility to necessary capital as they continue to innovate and expand. Matuszewski assured stakeholders that updates on clinical trials and listing progress will be provided as new information becomes available.
About BioStem Technologies, Inc.
BioStem Technologies, Inc. is at the forefront of med-tech innovation, specializing in the development and commercialization of allografts for regenerative therapies. The company focuses on utilizing perinatal tissue’s natural properties to create products that significantly impact lives. Through proprietary methods like BioREtain, designed to retain critical growth factors while protecting tissue structure, the company's commitment to quality is evident.
Accreditation and Quality Management
BioStem’s products are processed at an FDA-registered and AATB-accredited facility in Pompano Beach, Florida. The company adheres to current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP), ensuring that allografts such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® meet the highest standards in the industry. The American Association of Tissue Banks has acknowledged BioStem’s rigorous quality management systems, confirming the company’s commitment to safety and efficacy in its offerings.
Contact Information
For additional information about BioStem Technologies, Inc., interested parties can reach out via the following contact details:
Phone: 954-380-8342
Website: www.biostemtechnologies.com
Email: info@biostemtech.com
Frequently Asked Questions
What is the significance of the Form 10 filing for BioStem?
The Form 10 filing is a key step for BioStem, allowing it to become a fully reporting company with the SEC, enhancing its transparency and market credibility.
What is the current trading status of BioStem’s stock?
BioStem's stock continues to trade on the OTC market under the ticker symbol “BSEM” until it successfully uplists to Nasdaq.
How does BioStem plan to improve shareholder value?
By pursuing a Nasdaq listing, BioStem aims to enhance visibility, access to capital, and liquidity, ultimately driving greater shareholder value.
What products does BioStem offer?
BioStem offers a range of placental-derived allografts including AmnioWrap2™, VENDAJE®, and VENDAJE AC®, all designed for regenerative therapies.
How can stakeholders stay updated on BioStem’s progress?
BioStem plans to provide regular updates on its uplisting process and clinical trials to keep stakeholders informed.
